FORT COLLINS, CO—(Marketwired – February 07, 2018) – Armis Biopharma, Inc. (“Armis” or the “Company”), a late–stage clinical biopharmaceutical company with a growing pipeline of targeted anti–infective therapeutics designed to address antibiotic resistance and healthcare–associated infections, a serious and rapidly growing phenomenon, announced today that Mike Handley, Chief Executive Officer of Armis, will present at the BIO CEO & Investor Conference on Monday, February 12, 2018 at 3:15 p.m. EST in New York, NY.
As part of his presentation, Mr. Handley will provide a corporate overview as well as discuss the Company's plans to advance its lead product candidate Ximycinâ¢, initially being developed for targeted prophylaxis of surgical site infections in elective colorectal resection procedures typically related to inflammatory bowel disease, ulcerative colitis, diverticulitis or colon cancer. Armis is on track to initiate a pivotal Phase 3 registration study for its lead indication of Ximycin in 2018.
Ximycin, the Company's lead product candidate, is a patented, first–of–its–kind localized antimicrobial therapy derived from a combination of a gram–positive agent, vancomycin, and a gram–negative agent, gentamicin, two potent well–established and accepted agents. Ximycin utilizes a proprietary sustained–release delivery method via gel formulation, enabling temporally–extended, broad spectrum polymicrobial coverage in the incision site.
The Company recently announced that the U.S. Food and Drug Administration (FDA) has designated Ximycin as a Qualified Infectious Disease Product (QIDP) for prophylactic treatment of surgical site infections in high–risk patients undergoing non–emergent colorectal surgery.
In addition to the presentation, management will be available to participate in one–on–one meetings with qualified members of the investor community who are registered to attend the conference. To schedule a meeting, please contact the Company through the one–on–one meeting portal.
A live audio webcast of the presentation will be available on the Investors page of the Company's website (www.armisbiopharma.com). A webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days following the live presentation.
About Armis Biopharma, Inc.
Armis Biopharma is a late–stage clinical biopharmaceutical company with a growing pipeline of targeted anti–infective therapeutics designed to address antibiotic resistance and healthcare–associated infections, a serious and rapidly growing phenomenon.
The Company's lead product candidate, Ximycinâ¢, is a patented, first–of–its–kind localized antimicrobial therapy derived from a combination of a gram–positive agent, vancomycin, and a gram–negative agent, gentamicin, two potent well–established and accepted agents. Ximycinâ¢ utilizes a proprietary sustained–release delivery method via gel formulation, enabling temporally–extended, broad spectrum polymicrobial coverage in the incision site. Ximycin is initially being developed for use as a prophylactic therapy for the mitigation or prevention of multi–drug resistant surgical site infections (“SSIs”), including multi–drug resistant gram–negative and/or gram–positive infections.
Armis is also focused on developing and commercializing a proprietary, first–of–its–kind, peracid–based anti–infective technology and acquiring other synergistic technologies/products. For more information about the Company, visit www.armisbiopharma.com.
This press release contains certain forward–looking statements, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward–looking statements may be made by the Company from time to time. The Private Securities Litigation Reform Act of 1995 provides a safe–harbor for forward–looking statements. These statements may be identified by the use of forward–looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward–looking statements. Prospective investors are cautioned not to place undue reliance on such forward–looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward–looking statement, whether as a result of new information, future events or otherwise.